応用DNAサイエンスでは Q3のEPSの見積もりを1.1ドル上回ったが,収益目標を達成できず,株価上昇と分析者の評価が混じった. Applied DNA Sciences exceeded Q3 EPS estimates by $1.11, but missed revenue targets, leading to stock price increase and mixed analyst ratings.

応用DNA科学 (APDN) は,Q3の収益をEPS0.47ドルと報告し,分析者のコンセンサス推定を1.11ドル上回った. Applied DNA Sciences (APDN) reported Q3 earnings of $0.47 EPS, exceeding analysts' consensus estimates by $1.11. 収益は0.80Mドルで,予測された0.95Mドルを上回らず,同社の株価は0.01ドル上昇し,0.36ドルに達した. Despite generating $0.80M in revenue, falling short of the projected $0.95M, the firm's stock price increased by $0.01, reaching $0.36. HCウェイナライトは目標価格を1.50ドルに下げながら"買い"の評価を維持し,StockNews.comは"売る"の評価を出した. HC Wainwright lowered their target price to $1.50 while maintaining a "buy" rating, while StockNews.com issued a "sell" rating. APDNはDNA生産,検査サービス,DNAタグ付け,セキュリティ製品とサービスで活動しています. APDN operates in DNA production, testing services, and DNA tagging and security products and services.